Mar 29 2013
Market Research on Biomaterials and Protein Engineering Industry Products with Technology and Applications
The global biomaterials market is poised to grow at a CAGR of 15% from 2012 to 2017 to reach $88.4 billion by 2017 says the report "Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] – Global Forecasts to 2017". The global engineered protein products market is estimated to be worth $168 billion by 2017, growing at a CAGR of 10.94% from 2012 to 2017 says the report "Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017"
Major factors propelling the growth of the global biomaterial market include increased investments, funding and grants by government bodies' worldwide, incessant rise in the number of collaborations, conferences and research-related activities, technological advancements, increasing applications of biomaterials, and growing number of elderly people. Immunological and inflammatory reactions, stringent regulatory systems, issue of fracture fatigue and wear and reimbursement concerns are the major deterrents curbing the biomaterial market.
The global biomaterial market report available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=231675 says the industry witnesses a plethora of growth opportunities. Novel developments of biomaterial for wound healing, plastic surgery, tissue engineering, ophthalmology, and neurology, colossal pool of cardiac patients in Asia, rise of biomaterial market in China and Taiwan, and increased conferences and research-related activities in RoW countries are major factors influencing the growth of the biomaterial market. The burning issues affecting the growth of biomaterial market are challenges to tissue engineering and effect on suppliers by the Biomaterials Access Assurance Act.
The global biomaterial market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the biomaterial market in the years to come, followed by Europe. North American market growth is likely to be driven by increasing government investments in biomaterial sector, reimbursements offered by Centers for Medicare and Medicaid Services (CMS) and rising aging population who are the main consumers of biomaterials. The North American biomaterial market is expected to receive a significant push due to phenomenal increase in new products such as botox, botulinum toxins, and hyaluronic-based injectables.
Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications. The protein engineering market report available for purchase @ http://www.reportsnreports.com/Purchase.aspx?name=231673 says the industry is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.
The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Diagnostics is another segment in focus; monoclonal antibodies are being used extensively in diagnostics and in assays for research.
The report also profiles leading participants of the industry with their recent developments and other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).
Explore more biotechnology market reports @ http://www.reportsnreports.com/market-research/biotechnology/.